Please be advised that the format of evaluation reports shared on the NICE website has recently changed, for ease of user navigation between individual documents contained in the report.

It is a requirement of the new (PDF portfolio) format that Adobe Reader is used to view the document. Please follow the link at the bottom of this page to download Adobe Reader if required.

If you have any feedback on the new format please contact the Project Manager for this appraisal.

Hepatitis C (children and young people) - peginterferon alfa and ribavirin: evaluation report

01 Overview prepared by NICE
02 Full preceding guidance for TA75
03 Full preceding guidance for TA106
04 Assessment Report prepared by Southampton Health Technology Assessment Centre
05 Comments on the Assessment Report from the Manufacturer Roche
06 Comments on the Assessment Report from the Manufacturer Merck Sharp and Dohme
07 Comments on the Assessment Report from The Hepatitis C Trust
08 Comments on the Assessment Report from the Royal College of Nurses
09 Comments on the Assessment Report from the Department of Health
10 Response to comments on the Assessment Report prepared by Southampton Health Technology Assessment Centre
11 Executive summary of technology manufacturer’s submission - Roche (ribavirin)
12 Executive summary of technology manufacturer’s submission - Merck Sharp and Dohme (peginterferon alfa)
13 Consultee submission - Children's HIV Association
14 Consultee submission - Hepatitis C Trust
15 Consultee submission - NHS Humber
16 Clinical expert statement - Dr Rosie Hague
17 Clinical expert statement - Professor Deirdre Kelly
18 Clinical expert statement - Susan McRae
19 Clarifications from Assessment Group